ISRG Q2 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Intuitive Surgical delivered a standout second quarter for 2025, with non-GAAP EPS of $2.19 beating the $1.93 consensus by 13.22% and revenue of $2.44 billion topping estimates by 3.83% on 21.4% year-over-year growth, as analysts had closely watched … Read more Intuitive Surgical delivered a standout second quarter for 2025, with non-GAAP EPS of $2.19 beating the $1.93 consensus by 13.22% and revenue of $2.44 billion topping estimates by 3.83% on 21.4% year-over-year growth, as analysts had closely watched heading into the print. The primary engine behind the outperformance was procedure volume, with worldwide da Vinci procedures growing roughly 17% year-over-year and Ion procedures surging approximately 52%, together driving instruments and accessories revenue, the company's largest recurring stream, up 18% to $1.47 billion. System placements also accelerated, with da Vinci 5 units more than doubling to 180 from 70 a year ago, pushing systems revenue to $574.70 million from $448.20 million. Adding strategic momentum, the company secured European MDR certification and Japanese regulatory clearance for da Vinci 5 during the quarter. Looking ahead, management guided full-year da Vinci procedure growth of roughly 15.5% to 17%, while flagging an estimated tariff headwind of approximately 1.0% of revenue embedded in its non-GAAP gross margin outlook of 66% to 67%.